A new science-business paradigm in anticancer drug development

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• Cancer lacks specific molecular targets, hindering new drug development.
• Existing anticancer drugs offer limited improvements over current treatments.
• Drug resistance, a cancer hallmark, presents an opportunity for targeted therapy.

Purpose of the Study:

• To explore novel therapeutic strategies for cancer treatment.
• To investigate the potential of repurposing existing drugs and "failed" drugs for cancer therapy.
• To propose cost-effective therapeutic modalities using marketed and late-stage pharmaceutical products.

Main Methods:

• Analysis of molecular mechanisms in cancer.
• Exploitation of cancer hallmarks like drug resistance for therapeutic advantage.
• Repurposing of existing pharmaceutical agents and "failed" drugs.

Main Results:

• Unfavorable cancer hallmarks, such as drug resistance, can be leveraged for selective anticancer therapy.
• Existing drugs and "failed" drugs can be repurposed for novel therapeutic applications.
• Development of cost-effective, cancer-selective therapeutic kits using marketed and late-stage products is feasible.

Conclusions:

• Repurposing drugs offers a viable and economical approach to cancer treatment.
• Exploiting cancer's inherent characteristics can lead to more effective and selective therapies.
• The pharmaceutical industry can innovate by creating therapeutic kits from existing products for cancer care.